Document is current

Article History

Received: 14 October 2024

Accepted: 6 February 2025

First Online: 3 March 2025

Declarations

:

: Informed consent has been obtained from patients and approval have been granted by the Ethics Committee Heidelberg (University of Heidelberg, Germany; S-206/2011;S-356/2013) and Dana-Farber/Harvard Cancer Center Institutional Review Board; #99-224).

: RV is a current employee of Genmab Biotechnology Company, Copenhagen, Denmark. TZL is a current employee at Casma Therapeutics, Inc, Cambridge, MA, USA. CH has received honoraria from AbbVie, Janssen, Roche, Gilead, Takeda, Daiichi and personal fees from AbbVie, Janssen, Roche, Gilead, Takeda. BCG consults and serves on the Advisory board for MSD, Merck KGaA, Novartis, Adagene Inc., Bayer Healthcare and receives research funding from Taiho pharmaceuticals, Otsuka pharmaceuticals, Adagene Inc., Bayer Healthcare, Alx Oncology, Sanofi and Amgen. JRB has served as a consultant for Abbvie, Acerta/Astra-Zeneca, BeiGene, Genentech/Roche, Grifols Worldwide Operations, Hutchmed, iOnctura, Janssen, Kite, Loxo/Lilly, MEI Pharma, Numab Therapeutics, Pfizer, Pharmacyclics and received research funding from BeiGene, Gilead, iOnctura, Loxo/Lilly, MEI Pharma, TG Therapeutics. CUN has received consultancy fees and/or travel grants from Janssen, Abbvie, Novartis, Roche, Sunesis, Gilead, AstraZeneca, and CSL Behring, research support from Abbvie, AstraZeneca, Janssen and Novo Nordisk Foundation (NNF16OC0019302). TZ has received honoraria from Roche, Abbvie, Gilead, Janssen, AstraZeneca, Eli Lilly and Janpix. MSD has received institutional research funding from Ascentage Pharma, MEI Pharma, Novartis, Surface Oncology, TG Therapeutics and personal consulting income from AbbVie, Adaptive Biosciences, Ascentage Pharma, AstraZeneca, BeiGene, BMS, Eli Lilly, Genentech, Genmab, Janssen, Merck, Mingsight Pharmaceuticals, Secura Bio, TG Therapeutics, and Takeda. Other authors have no potential conflicts of interest or relevant disclosures.